The definition of pulmonary hypertension: history, practical implications and current controversies
- PMID: 35035548
- PMCID: PMC8753640
- DOI: 10.1183/20734735.0076-2021
The definition of pulmonary hypertension: history, practical implications and current controversies
Abstract
The definition of pulmonary hypertension (PH) is based on a growing body of evidence and represents the result of ongoing discussions within the PH community over the past 50 years. In 2018, the most recent World Symposium on Pulmonary Hypertension introduced significant changes in the definition of PH by lowering the mean pulmonary arterial pressure threshold to >20 mmHg and (re)introducing the pulmonary vascular resistance ≥3 WU cut-off for all forms of pre-capillary PH. These changes and their potential clinical impact have been the subject of lively discussions in the community and some important questions and controversies have been identified. In this review we aim to present the development of the definition of PH over the past decades and discuss the main arguments that led to relevant modifications. In addition, we address the practical implications of the most recent changes and controversies that still exist.
Educational aims: To review the historical development of the definition of pulmonary hypertension.To discuss practical implications and current controversies of the currently recommended definitions of pulmonary hypertension and pulmonary arterial hypertension.
Copyright ©ERS 2021.
Conflict of interest statement
Conflict of interest: G. Kovacs reports personal fees and non-financial support from Actelion, Janssen, Bayer, GSK, MSD, Boehringer Ingelheim, Novartis, Chiesi, Vitalaire, Ferrer, AOP outside the submitted work. Conflict of interest: H. Olschewski reports grants from Bayer, Unither Pharmaceuticals, Actelion Pharmaceuticals Ltd., Roche, Boehringer Ingelheim and Pfizer Inc., personal fees from Gilead Sciences Inc., Encysive Pharmaceuticals Ltd. and Nebu-Tec, personal fees and non-financial support from Bayer, Unither Pharmaceuticals, Actelion Pharmaceuticals Ltd., Pfizer Inc., Eli Lilly, Novartis, AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini, MSD and GSK outside the submitted work.
Figures
References
-
- Hatano S, Strasser T. Primary Pulmonary Hypertension: Report on a WHO Meeting, Geneva, 15-17 October 1973. Geneva, WHO, 1975. https://apps.who.int/iris/handle/10665/39094
-
- WHO Expert Committee on Chronic Cor Pulmonale & World Health Organization. Chronic cor pulmonale: report of an Expert Committee [meeting held in Geneva from 10 to 15 October 1960]. Geneva, WHO, 1961. https://apps.who.int/iris/handle/10665/40483
-
- Rich S. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, September 6–10. 1998. Geneva, WHO, 1998.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous